Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

69 results about "Benzocaine" patented technology

This medication is used on the skin to stop itching and pain from certain skin conditions (such as scrapes, minor burns, insect bites) and to treat minor discomfort and itching caused by hemorrhoids and certain other problems of the genital/anal area (such as anal fissures, itching around the vagina/rectum).

Non-flammable topical anesthetic liquid aerosols

A topical liquid aerosol formulation for accurate metered dose delivery has been developed which includes a concentrate comprising a local anesthetic in a non-alcohol solvent and a hydrofluorocarbon (HFC) propellant. In the preferred embodiment, the concentration of the non-alcohol solvent in the concentrate is between about 75% and 85% by weight of the formulation. In the most preferred embodiment, the non-alcohol solvent is a water-soluble polyol such as ethylene glycol, propylene glycol, glycerol, diethylene glycol, dipropylene glycol, oligoalkylene glycols, liquid polyalkylene glycols, or combinations thereof. In one embodiment, the concentration of the local anesthetic in the concentrate is between about 15% and 25% by weight. In the preferred embodiment, the hydrofluorocarbon propellant is 1,1,1,2-tetrafluoroethane 1,1,1,2,3,3,3-heptafluoropropane or combinations thereof, in a concentration between about 35% and 65% by weight of the final formulation, more preferably between about 45% and 55% by weight of the final formulation. A particularly preferred formulation includes benzocaine, tetracaine, and butylaminobenzoate, wherein the concentration of benzocaine in the concentrate is 14% by weight, the concentration of tetracaine in the concentrate is 2% by weight, and the concentration of butylaminobenzoate in the concentrate is 2% by weight. It has been found that the formulation is more stable in the substantial absence of oxygen. The formulation is preferably administered using a metered dose device for release of a controlled amount of the local anesthetic.
Owner:PRECISION DERMATOLOGY

Method for use of microdialysis

InactiveUS20070106140A1Fast resultsAccurately permeabilitySensorsBlood characterising devicesResting timeHigh rate
It has been surprisingly found that very accurate measurements of mass transfer can be made rapidly by permitting diffusion of an agent desired to be measured into a small, known volume of receiver or out of a known volume of donor, then rapidly pumping or flushing (“pulsing”) the receiver with a known volume of fluid. More specifically, a novel method of transferring small quantities of a contained material (either dissolved or suspended) between two media, based on such pulsing, hereinafter called pulsatile microdialysis (PMD), is disclosed. In a preferred embodiment, one medium (the dialysate) is inside a small, permeable tube (microdialysis probe window) and the other (external medium) is outside. The transfer of material between the two media can be utilized, for example, to sample drug concentrations in the external medium, or the release of drugs from systems within the dialysate, or for other measurements as disclosed herein. In PMD, a dialysate fluid is pumped into a microdialysis probe window, allowed to occupy the probe window while at rest for some resting time, and then flushed at a high rate out as a single pulse. A model that is based on a Fick's Laws was solved, and equations were derived to calculate the effects of various experimental parameters. The models were verified against experimental data using methazolamide, warfarin and benzocaine as test drugs. The data followed the mathematical models. For cases in which the concentration of free drug in the medium outside the probe was constant or changed very slowly, the concentration calibration plots were linear. In simulated first order uptake studies, the PMD and direct donor sampling data were in nearly exact agreement with the theoretical values of k=0.09 min−1. In another experiment, the free concentration of warfarin sodium in the medium outside the probe was made to decline rapidly in a known first order manner, with rate constants as high as 0.077 sec−1. The concentration in the external medium calculated from the PMD data was in nearly exact agreement with the known concentration at various times, and the experimental rate constants were in nearly exact agreement with the theoretical rate constants. For binding of methazolamide to activated charcoal, and for the binding of sodium warfarin to bovine serum albumin, PMD was able to generate sufficient data points to accurately characterize the rapid initial binding. This invention demonstrates that PMD is an accurate method of sampling drug concentrations and measuring rates and extents of a number of processes, including protein binding, adsorption to binding agents such as activated charcoal, release from microemulsion drug delivery systems, and the determination of drug diffusion coefficients, and for various other purposes which will occur to those skilled in the art. Compared to known methods such as traditional (continuous) microdialysis, the present invention offers the ability to sample more frequently, and over much shorter time intervals, thereby accurately obtaining data not heretofore available.
Owner:BELLANTONE ROBERT ARTHUR

Preparation method of chemical intermediate benzocaine

The invention discloses a preparation method of chemical intermediate benzocaine. The preparation method of the chemical intermediate benzocaine comprises the steps: S1, adding 4-nitrobenzoic acid, absolute ethanol, a solid catalyst and a water-carrying agent into a reaction container with a water segregator and performing hot reflux for 1 to 6 hours, wherein the solid catalyst takes magnesium aluminum hydrotalcite as a precursor and modified nanometer bentonite as a carrier, the weight of the precursor is 25 to 45 percent that of the carrier, and the solid catalyst is prepared by grinding and mixing the precursor and the carrier uniformly and calcining at 500 to 700 DEG C for 2 to 4 hours; S2, discharging water out of the water segregator, replenishing the absolute ethanol and continuously performing reflux and water segregation until no water drops occur; S3, after the reaction is finished, filtering when the reaction liquid is hot and putting the filtrate into a hydrogenation kettle to perform hydrogenation reaction; S4, after the hydrogenation is finished, performing heat filtration to remove the catalyst from the system, cooling and filtering under the protection of nitrogen, and drying to obtain the chemical intermediate benzocaine. The preparation method of the benzocaine, provided by the invention, is high in conversion rate; the solid catalyst has high catalytic efficiency and can be repeatedly used, and the catalytic efficiency is not obviously reduced after the catalyst is repeatedly used for 50 times.
Owner:安徽金邦医药化工有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products